F the combination of LY Bcl xL siRNA treatment

to test pharmacologic accumulation compared between normal and cancer cells, a cell of cancer cell lines and normal epithelial cell lines were treated with the aforementioned Hedgehog inhibitor problem simultaneously. In line with Fig. 4A and B, AZD6244 along with API 2 successfully killed the cancer cells, whereas the same treatment caused little toxicity within the normal epithelial cells. Together, our results suggest that combining AZD6244 with other clinical pharmacologic agents that increase FOXO3a activity, including API 2, may promote the effectiveness of AZD6244 treatment and even sensitize AZD6244 immune cells to growth suppression. Given the that the mixture of AZD6244 and API 2 improved FOXO3a nuclear translocation, improved Bim ally association, recovered Bim transcriptional activation, and sensitized AZD6244 resistant cancer cells to growth suppression and cell death, we imagine that FOXO3a activation is a significant factor in avoiding AZD6244 weight. The preferential killing impact in cancer cells versus normal cells might also gain AZD6244 treatment by Skin infection preventing potential negative effects in normal cells. A model showing molecular reactions toward AZD resistant and AZD sensitive and painful cancer cells is proposed in Fig. 5B. So far, AZD6244 has been under analysis in 21 clinical trials with about 10 different cancer types including breast cancer, colon cancer, lung cancer, melanoma, kidney cancer, hepatocellular carcinoma, pancreatic cancer, ovarian cancer, acute myelogenous leukemia, and thyroid cancer in which AZD6244 has demonstrated promising therapeutic effects specially in cancers with BRAF strains with lower toxicity. Other MEK inhibitors including PD 0325901 are also demonstrated to have promising anti-tumor action in mouse models but ocular and neurologic toxicity was presented in a phase I canagliflozin clinical study. In Fig. 5A, the mix of API and AZD6244 2 in significant cell death in the five different cancer cell lines but not in the three different normal cell lines, suggesting that AZD6244 selectively targets cancer cells and has relatively low toxicity to normal cells. AKT and ERK can be activated oncogenic kinases in human cancers. Curiously, both kinases target the same tumor suppressor gene, FOXO3a. It was known that AKT and ERK phosphorylate FOXO3a at different phosphorylation sites. Similarly, the phosphorylation of FOXO3a by these oncogenic kinases in FOXO3a translocation from the nucleus to the cytoplasm and subsequent destruction. Taxol, LY2940024, and API 2 were demonstrated to efficiently prevent PI3K AKT pathway and activate FOXO3a nuclear translocation and activity. Within our recent study, we confirmed that inhibition of both RAS/MEK/ ERK and PI3K/AKT pathways enhances FOXO3a activity. We showed that the service of FOXO3a and its downstream gene Bim is specially essential for the maximal sensitivity of cancer cells responding to AZD6244 treatment.